Table 2.
Beta-blockers vs. placebo according to left ventricular ejection fraction at baseline
| Baseline heart rhythm and LVEF category | All-cause mortality |
Cardiovascular death |
Cardiovascular hospitalization |
Composite of cardiovascular death | ||||
|---|---|---|---|---|---|---|---|---|
| or cardiovascular hospitalization | ||||||||
| Events/N | HR (95% CI); P-value | Events/N | HR (95% CI); P-value | Events/N | HR (95% CI); P-value | Events/N | HR (95% CI); P-value | |
| Sinus rhythm | ||||||||
| <20% | 623/2531 | 0.70 (0.60-0.83); P < 0.001 | 517/2531 | 0.67 (0.56-0.80); P < 0.001 | 762/2407 | 0.70 (0.60-0.81); P < 0.001 | 990/2407 | 0.68 (0.60-0.77); P < 0.001 |
| 20-25% | 619/3862 | 0.76 (0.65–0.89); P = 0.001 | 521/3862 | 0.78 (0.65–0.92); P = 0.004 | 1033/3807 | 0.75 (0.66–0.85); P < 0.001 | 1273/3807 | 0.75 (0.67–0.84); P < 0.001 |
| 26–34% | 631/5043 | 0.75 (0.64–0.88); P < 0.001 | 504/5042 | 0.73 (0.61–0.87); P < 0.001 | 1118/4972 | 0.84 (0.74–0.94); P = 0.003 | 1384/4972 | 0.80 (0.72–0.88); P < 0.001 |
| 35–39% | 189/1919 | 0.67 (0.50–0.90); P = 0.007 | 156/1919 | 0.72 (0.52–0.99); P = 0.041 | 401/1907 | 0.75 (0.61–0.91); P = 0.004 | 490/1907 | 0.74 (0.62–0.88); P = 0.001 |
| 40–49% | 55/570 | 0.59 (0.34–1.03); P = 0.066 | 38/570 | 0.48 (0.24–0.97); P = 0.040 | 144/566 | 0.95 (0.68–1.32); P = 0.76 | 164/566 | 0.83 (0.60–1.13); P = 0.23 |
| ≥50% | 24/241 | 1.79 (0.78–4.10); P = 0.17 | 15/241 | 1.77 (0.61–5.14); P = 0.29 | 50/241 | 0.66 (0.37–1.18); P = 0.16 | 54/241 | 0.66 (0.38–1.15); P = 0.14 |
| Atrial fibrillation | ||||||||
| <20% | 143/492 | 1.23 (0.88–1.74); P = 0.23 | 124/492 | 1.16 (0.80–1.67); P = 0.44 | 148/471 | 0.97 (0.69–1.35); P = 0.85 | 201/471 | 0.96 (0.72–1.28); P = 0.79 |
| 20–25% | 159/867 | 0.74 (0.54–1.02); P = 0.07 | 136/867 | 0.77 (0.54–1.08); P = 0.13 | 234/856 | 0.75 (0.58–0.98); P = 0.032 | 291/856 | 0.75 (0.59–0.95); P = 0.015 |
| 26–34% | 208/1093 | 0.98 (0.74–1.29); P = 0.87 | 166/1093 | 0.98 (0.72–1.34); P = 0.92 | 321/1083 | 1.01 (0.81–1.26); P = 0.92 | 390/1083 | 0.93 (0.76–1.13); P = 0.47 |
| 35–39% | 59/363 | 0.92 (0.53–1.58); P = 0.75 | 46/363 | 0.67 (0.35–1.25); P = 0.21 | 99/358 | 0.90 (0.60–1.36); P = 0.62 | 121/358 | 0.94 (0.65–1.37); P = 0.76 |
| 40–49% | 32/146 | 1.30 (0.63–2.67); P = 0.48 | 22/146 | 0.86 (0.36–2.03); P = 0.73 | 34/143 | 1.15 (0.57–2.32); P = 0.69 | 46/143 | 1.06 (0.58–1.94); P = 0.84 |
| ≥50% | 8/73 | 0.86 (0.19–3.94); P = 0.85 | 4/73 | 1.00 (0.10–9.91); P = 1.00 | 26/73 | 1.33 (0.56–3.16); P = 0.52 | 27/73 | 1.17 (0.51–2.71); P = 0.71 |
CI, confidence interval; HR, hazard ratio (adjusted for baseline characteristics and stratified by trial); n, number of individuals.